Resultados y conclusiones: Aunque lenacapavir y cabotegravir son altamente eficaces, su acceso a LMICs (en español, países de renta baja y media) llega años tarde. Las causas principales son las licencias tardías, precios elevados y una producción centralizada. #HIVAccess

DC Health Officials Eliminate Co-Pays for HIV Care to Address Racial Disparities DC eliminates co-pays for HIV care to address racial equity and improve access for communities.

D.C. health officials are taking a groundbreaking step by eliminating co-pays for HIV care, aiming to bridge the gap in healthcare access for communities of color.

Click to read more!

#US #HIVAccess #WashingtonDCHealthcare #CitizenPortal #HealthEquity